Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

67.86 +0.85 (+1.27%)
Official Closing Price Updated: 4:15 PM EDT, May 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,831,972
Open 67.01
Bid (Size) 67.56 (4)
Ask (Size) 67.72 (1)
Prev. Close 67.01
Today's Range 66.85 - 67.97
52wk Range 64.33 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 4.42%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns. 
Via InvestorPlace
Market Whales and Their Recent Bets on GILD Options
Via Benzinga

Performance

YTD
-18.48%
-18.48%
1 Month
+0.82%
+0.82%
3 Month
-7.51%
-7.51%
6 Month
-8.94%
-8.94%
1 Year
-13.89%
-13.89%

More News

Read More
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
From Gilead Sciences, Inc.
Via Business Wire
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
Via Benzinga
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Gilead Sciences, Inc.
Via Business Wire
Why NASDAQ:GILD qualifies as a good dividend investing stock.
Via Chartmill
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,300 Today
Via Benzinga
Gilead Sciences Unusual Options Activity For May 06
Via Benzinga
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Via InvestorPlace
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
From Gilead Sciences, Inc.
Via Business Wire
Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back
Via InvestorPlace
How Is The Market Feeling About Gilead Sciences?
Via Benzinga
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
Via InvestorPlace
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Gilead Sciences Unusual Options Activity
Via Benzinga
Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss?
Via Investor's Business Daily
Exposures COVID-19
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
3 Dividend Stocks to Buy at a 52-Week Low in April
Via InvestorPlace
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Gilead Sciences Announces First Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.